-+ 0.00%
-+ 0.00%
-+ 0.00%

Atossa Therapeutics prices registered direct offering for USD 4.5 million upfront, up to USD 16.5 million with warrants

PUBT·06/11/2026 12:02:15
Listen to the news
Atossa Therapeutics prices registered direct offering for USD 4.5 million upfront, up to USD 16.5 million with warrants
  • Atossa Therapeutics priced a registered direct offering expected to raise about USD 4.5 million in gross proceeds.
  • Deal includes 1,363,638 common shares or equivalents, Series A warrants, and short-term Series B warrants for up to 1,363,638 shares each.
  • Warrants become exercisable six months after issuance; Series A expires in 5.5 years, Series B in 2 years.
  • Full cash exercise could add about USD 12 million in gross proceeds, lifting total potential proceeds to about USD 16.5 million.
  • Closing expected on or about June 12, 2026; Rodman & Renshaw serving as exclusive placement agent.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606110800PR_NEWS_USPR_____SF81455) on June 11, 2026, and is solely responsible for the information contained therein.